TrialClinical lymphoma, myeloma & leukemia2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papercites it